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1. Introduction  
Psoriasis is a chronic inflammatory disease affecting about 3% of the worldwide population 
(Gottlieb A et al, 2007). 
Recent findings have shown that the previous concept “ psoriasis as a disease of healthy 
people” must be revisited into psoriasis as a complex entity with multisistemic involvement.   
Although the overall mortality attributed to psoriasis is about 0.64 deaths per 100 000 
psoriatic patients annually in the USA, erythrodermic and generalized pustular soriasis, are 
associated with a greater risk of mortality and morbidity (Boyd AS et al, 1989;  Prystowsky 
JH et al, 1995). 
Psoriasis can be associated with other disease, such as metabolic syndrome, which may have 
a major impact on quality of life, morbidity and mortality. 
The aim of this chapter is to focus on  two newly emergent comorbidities in psoriatic 
patients,  the cardiovascular disease (CVD) and the metabolic syndrome (MetS). 
2. The metabolic syndrome 
The metabolic syndrome  (MetS) is  a cluster of risk factors including obesity, atherogenic 
dyslipidaemia, hypertension, glucose intolerance and a proinflammatory and prothrombotic 
state  predisposing the patients to cardiovascular diseases (CVD),  type 2 diabetes (DM), 
renal failure and stroke (Gisondi et al, 2007). 
Furthermore, it has recently been suggested that the metabolic syndrome might be a risk 
factor for cancer, in particular colon cancer (Gottlieb A et al, 2007). 
The MetS prevalence in Western Europe population  ranges from  15% to  35% and  it 
strictly correlates with age, increasing sharply after the age of 60 (Gisondi et al, 2007).  
The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) 
have proposed the criteria for the metabolic syndrome diagnosis; other organizations, such 
as The World Health Organization (WHO) and the European Group on Insulin resistance, 
agree with it in the essential components, differing from it in the details and criteria (Chung 
CP et al, 2005). 
According to NCEP ATPIII the diagnosis of  MetS requires at least three of these following  
criteria: 
www.intechopen.com
 Psoriasis 108 
 Abdominal obesity, defined as waist circumference ≥ 102 cm in men and ≥ 88 cm in 
women 
 Tryglicerides plasma levels ≥ 150 mg/dl 
 HDL cholesterol plasma levels less than 40 mg/dl in men and 50 mg/dl in women 
 Blood pressure more than 130 mmHg (systolic) and 85 mmHg (diastolic)  
 Fasting plasma glucose levels more than 100 mg/dL  [Grundy et al., 2005] 
It is now thought that non-alcoholic fatty liver disease (NAFLD)  is a component of 
metabolic syndrome, that may progress to steatoepatitis (NASH) with  complications of 
fibrosis and cirrhosis (Capeau J, 2008). 
Recent study have demonstrated that the prevalence of metabolic syndrome is 
significantly higher in psoriatic patients compared to controls after the age of 40 years  
and  psoriatic patients have an increased risk for the individual components of MetS 
(Gisondi et al, 2007). 
Moreover, the association between psoriasis and metabolic syndrome is also true for mild 
severity psoriasis and it is independent from the tendency of psoriatic patients to be obese 
( Mallbris L et al, 2006; Neimann AL et al, 2006; Sommer DM  et al, 2006). 
Although the link between psoriasis and metabolic syndrome is not completely elucidated, 
the pathophysiology of both these entities shows many shared cytokines contributing to the 
underlying chronic inflammatory status. 
It is known that both innate and adaptive immunity are involved in psoriatic 
pathogenesis and, in particular, NK cells appear crucial in the inflammatory process 
initiation, with an increased release of  proinflammatory cytokines, such as TNF-alpha 
and IFN-gamma and the subsequent interaction with TH1 and Th17 cells (Teunissen 
MBM et al , 2007). 
Dysregulation of T-cell antigen presenting cell interactions and overexpression of   
proinflammatory cytokines lead to the hyperproliferation of keratinocytes and the activation 
of neutrophils and endothelial cells until the development of the characteristic psoriatic skin 
lesions (Kimball AB et al, 2008). 
The molecular mechanisms involved in psoriasis-associated dysregulation of metabolic 
functions are believed to be due to an underlying low and persistent inflammatory status 
with increased levels of proinflammatory factors, such as tumor necrosis factor-alpha and 
IL-6 (Fig.1). 
TNF-alpha is a proinflammatory cytokine produced by many cell lines, such as 
keratinocites, T  cells,  NK cells, dendritic cells, neutrophils,  mast cells and adipocytes 
(Ronti T et al, 2006). 
It is expressed as a 26-kD cell surface trans-membrane protein that undergoes cleavage to 
produce a 17-kD soluble, biologically active form of TNF-α (Ronti T et al, 2006). 
IL-6, a pleiotropic circulating cytokine, shows multiple effects ranging from inflammation to 
host defence and tissue injury. It is secreted by many cell types, including immune cells, 
fibroblasts, endothelial cells, skeletal muscle and adipocytes (Ronti T et al, 2006). 
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Fig. 1. The molecular mechanisms involved in psoriasis-associated dysregulation of 
metabolic function. 
3. Obesity and psoriasis 
Among different MetS components, the association between obesity and psoriasis is the best 
documented.  
Several studies have shown that the severity of PsO may be linked to obesity  and a 
population-based study of mild or severe PsO has demonstrated that the risk of obesity was 
significantly increased in PsO patients compared with healthy controls. Unlike in other 
inflammatory diseases, such as rheumatoid arthritis, the risk of obesity is strongly 
associated with disease severity (Sterry W et al, 2004). 
Although it is controversial if psoriasis is the result or the cause of obesity itself , recent data 
support the obesity is a consequence of psoriasis (Henseler T et al, 1995; Neimann AL  et al, 
2006; Herron MD et al. 2005). 
Obesity is considered  the main pathogenic factor in the metabolic syndrome and it is 
characterized by a low and persistent sistemic inflammatory status, whose mainstay is  the 
adipose tissue (Greenberg et al., 2006). 
Adipose tissue is principally divided into two compartments, subcutaneously and centrally: 
the central one is characterized by omental adipose tissue and other intra-abdominal fat 
sources such as mesenteric fat. Central adipose tissue, also called  visceral fat,  is considered 
more metabolically active than peripheral subcutaneous fat (Kershaw EE et al, 2004; Galic S 
et al, 2010). 
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The importance of adipose tissue location in terms of dysmetabolism risk is evident:  
patients with excess visceral fat (central obesity) show an higher risk of developing insulin 
resistance  and the features of the metabolic syndrome than patients with excess 
subcutaneous fat (Kissebach AH et al, 1982). 
One of the most commonly used antropometric indexes is BMI (Body mass index), which 
measures adiposity and body composition as weight in kilograms divided by the square 
ofthe height measurement in metres (kg/m2).  BMI have high specificity, but low sensitivity 
to identify adiposity and excess body fat (Okorodudu DO et al, 2010). 
Waist circumference (WC), alone or  in combination with BMI, has been shown to be an 
accurate predictor of visceral fat directly reflecting total abdominal fat mass but failing to 
quantify the visceral and subcutaneous fat compartments individually (Kashihara H et al, 
2009). 
The visceral adipose tissue is not only an energy storage organ, but also an important 
component of the immune system through the adipocytes’ expression of toll receptors and a 
real active endocrine organ producing  proinflammatory cytokines (TNF-alpha, IL-6), free 
fatty acids, procoagulant molecules and bioactive products called adipokines (Ronti et al, 
2006).  
Many adipokines have been identified, such as leptin, visfatin, resistin and adiponectin; they 
act in a communications network with other tissues and organs such as the skeletal muscle, 
adrenal cortex, brain and sympathetic nervous system and participate in appetite and 
energy balance, immunity, insulin sensitivity, angiogenesis, blood pressure, lipid 
metabolism and haemostasis (Ronti T et al, 2006). 
In particular, leptin and resistin appear to be two proinflammatory cytokines, while 
adiponectin has anti-inflammatory properties (Ronti T et al, 2006). 
Leptin, a 16-kD adipocyte-derived cytokine, is synthesized and released from fat cells in 
response to changes in body fat. Leptin circulates partially bound to plasma proteins and 
enters the CNS by diffusion through capillary junctures in the median eminence and by 
saturable receptor transport in the choroid plexus. In the hypothalamus, leptin binds to 
receptors that stimulate anorexigenic peptides such as proopiomelanocortin and cocaine- 
and amphetamine-regulated transcript and inhibit orexigenic peptides, such as 
neuropeptide Y. Leptin reduces intracellular lipid levels in skeletal muscle, liver and 
pancreatic beta cells, thereby improving insulin sensitivity. There is strong evidence 
showing that the dominant action of leptin is to act as a ‘starvation signal’: leptin declines 
rapidly during fasting.Therefore, leptin deficiency was perceived as a state of unmitigated 
starvation, leading to compensatory responses, such as hyperphagia, decreased metabolic 
rate and changes in hormone levels, designed to restore energy balance. The concept of 
‘leptin resistance’ was introduced when increased adipose leptin production was observed 
in obese individuals, who were not leptin-deficient. Moreovere, some studies suggest leptin 
may affect vascular structure with an angiogenic activity and contributes to arterial 
thrombosis through the platelet leptin receptor. Leptin also stimulates production of 
reactive oxygen species as a result of monocyte activation. Therefore, in an obese subject 
leptin may no longer be able to regulate caloric intake and energy balance, but may still 
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exert its angiogenic activity and production of reactive oxigen species, which affect vessel 
walls (Ronti T et al, 2006). 
Resistin is a dimeric protein. In murine models, obesity is associated with rises in 
circulating resistin concentrations. Resistin increases blood glucose and insulin 
concentrations and impairs hypoglycaemic response to insulin infusion. In obese mice, 
antiresistin antibodies decrease blood glucose and improve insulin sensitivity: these data 
support the hypothesis that in obese rodents, resistin induces insulin resistance and 
contributes to impaired insulin sensitivity. In humans, the physiological role of resistin 
must be elucidated and its role in obesity and insulin resistance and/or diabetes is 
controversial. In humans, as resistin is primarily produced in peripheral blood monocytes 
and its levels correlate with IL-6 concentrations. the question of its inflammatory role has 
been raised (Ronti et al, 2006). 
Four genes encode for resistin in the mouse and two in humans. Some genetic case 
control studies demonstrated genetic variations in the resistin gene are associated with 
insulin resistance and obesity in humans. Others show that the very low resistin mRNA 
expression in isolated human adipocytes does not correlate consistently with insulin 
resistance or obesity, making the role of human resistin in insulin resistance unclear. No 
differences have been observed in resistin expression in adipocytes from normal, insulin-
resistant, and type 2 diabetic individuals. Mc Ternan et al. reported greater resistin 
mRNA expression in fat depots in the abdomen than in the thigh, suggesting human 
resistin could play a role in obesity-related insulin resistance (McTernan et al, 2002; Ronti 
et al, 2006). 
Adiponectin is almost exclusively expressed in white adipose tissue, whose expression is 
inhibited by IL- 6 and TNF-α.   Unlike most adipokines, adiponectin expression and 
serum concentrations are reduced in obese and insulin-resistant states and,  in vivo, high 
plasma adiponectin levels are associated with reduced risk of myocardial infarction. 
Although further studies are needed to clarify whether adiponectin independently 
predicts coronary heart disease events, in men with type 2 diabetes, increased adiponectin 
levels are associated with a moderately decreased risk of coronary heart disease. The 
association seems to be mediated in part by the effects of adiponectin on high-density 
lipoprotein cholesterol (HDL), through parallel increases in both.  Moreover, it has been 
demonstrated that weight loss, caloric restriction and thiazoladinedione treatment 
increase adiponectin plasma levels and gene expression in white adipose tissue (Ronti et 
al, 2006). 
Recent studies have evidenced  a high leptin levels and  decreased serum levels of 
adiponectin in obesity, insulin-resistent PsO patients and they emphasized an inverse 
correlation between serum levels of adiponectin and IL-6 (Satapathy SK et al, 2004). 
The precise physiological events leading to the initiation of the inflammatory response in 
obesity remain incompletely understood. One theory underlined that the expansion of 
adipose tissue leads to adipocyte hypertrophy and hyperplasia with a consequent local 
oxygen supply, cell hypoxia and the activation of cellular stress pathways releasing 
proinflammatory cytokines and signals.  These proinflammatory chemokines attract pro-
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inflammatory macrophages into the adipose tissue with the creation of crown-like structures 
around hypertrophic dead or dying adipocytes. Furthermore, these macrophages release 
cytokines that stimulate an inflammation in neighboring adipocytes developing a vicious 
circle (Esposito K et al, 2004; Das UN, 2001). 
Thus, excess adipose tissue results in elevated levels of pro-inflammatory adipokines, 
resulting in an imbalance between increased inflammatory stimuli and decreased anti-
inflammatory mechanism leading to persistent low-grade inflammation (Wajchenberg BL et 
al, 2000; Esposito K et al, 2004; Das UN, 2001). 
Among proinflammatory cytokines, TNF-a and IL-6  represent  two  driving cytokines, 
which link psoriasis with many  MetS components, such as obesity-related insulin-resistance 
(Ronti T et al, 2006). 
In humans TNF-α is synthesized and secreted by adipocytes and stromovascular cells: 
adipose tissue TNF-α is not secreted in systemic circulation and acts in an autocrine and 
paracrine pathways. Adipose tissue TNF-α mRNA correlates with body mass index, 
percentage of body fat and hyperinsulinaemia; weight loss decreases TNF-α levels (Ronti T 
et al, 2006). 
TNF-α modifies the gene expression profile of adipocytes and liver with an increased release 
and production of FFAs, cholesterol and VLDL; elevated IL-6 levels appears  to be 
associated with decreased levels of HDL cholesterol, which  may contribute to a state of 
chronic inflammation (Gottlieb A et al, 2008). 
 
Fig. 2. The vicious circle linking obesity and hyperinsulinemia 
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Moreover, levels of soluble TNF-α receptors are directly  proportional to total and LDL 
cholesterol concentrations and inversely correlated with certain HDL cholesterol subfraction 
levels (Gottlieb A et al, 2008). 
Obesity-induced chronic inflammation is a key component in the pathogenesis of insulin 
resistance ( Fig.2). 
4. Insulin-resistance 
Several studies have demonstrated a potential association between PsO and increased 
serum fasting glucose levels, hyperinsulinemia, insulin-resistance, and type 2 diabetes. 
However, insulin resistance does not significantly correlate  with PsO disease severity and 
duration (Gottlieb A et al, 2008). 
Insulin resistance is a characteristic feature of most patients with Type 2 diabetes mellitus 
and is one of the MetS clinical features. Insulin is a pleiotropic hormone stimulating nutrient 
transport into cells, regulating gene expression, modifying enzymatic activity and 
regulating energy homeostasis (De Luca C et al, 2008). 
Insulin exerted to these multiple functions through  several intracellular signaling 
cascades, such as  the phosphatidylinositol 3-kinase (PI3K)-AKT (also called protein 
kinase B (PKB)) pathway and the Ras-mitogen activated protein kinase (MAPK) pathway. 
PI3K-AKT is largely responsible for insulin action on glucose uptake and in the 
suppression of gluconeogenesis, while MAPK mediates gene expression and controls cell 
growth and differentiation, interacting with the first pathway. The insulin action is 
evidenced on target tissue, such as liver, adipose tissue and skeletal muscle (De Luca C et 
al, 2008). 
In the liver, insulin regulates glucose metabolism depending on the meal or starvation, 
while in adipose tissue insulin signaling results in decreased hormone sensitive lipase 
activity and this anti-lipolytic effect inhibits free fatty acid efflux out of adipocytes (De Luca 
C et al, 2008). 
Increased levels of  TNF-alpha,  IL-6 and FFAs produced by excess visceral adipose tissue 
can cause insulin resistance in adipose tissue, skeletal muscle and liver by inhibiting insulin 
signal transduction and  they can determine the production of other inflammatory-related 
factors, such as CRP (Gottlieb A et al, 2008). 
TNF-alpha causes a decrease in the autophosphorylation of tyrosine residues of insulin 
receptor (IR) and phosphorylation of insulin receptor substrate 1 (IRS-1) (Hotamisligil GS, 
2003). 
Thus, in psoriasis obesity and insulin resistance have a proinflammatory effect perpetuated 
through a positive feedback loop in PsO patients. 
5. NAFLD  
The liver plays a central role in lipid metabolism, importing serum free fatty acids and 
manufacturing, storing and exporting lipids and lipoproteins (Adams LA et al, 2005). 
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NAFLD is the acronym for nonalcoholic fatty liver disease and it includes a wide spectrum 
of liver pathology, from hepatocellular steatosis to nonalcoholic steatohepatitis (NASH) 
(Browning JD et al, 2004). 
The prevalence of NAFLD is 10–25% in the western world and it is a an emergent condition 
now recognized as the most frequent cause of abnormal liver tests, especially in obese 
individuals (Papatheodoridis GV et al, 2007). 
NAFLD is considered the hepatic manifestation of the metabolic syndrome closely 
associated to visceral obesity and insulin resistance (Marchesini G et al, 2003; Tsochatzis EA 
et al, 2009). 
Adipocytokines, free fatty acids, mitochondrial dysfunction, bacterial endotoxin and 
vascular disturbance have all been implicated in the development of hepatic inflammation 
and fibrosis in patients with NAFLD (Adams LA et al, 2005). 
The pathogenesis of NAFLD is currently seen as a two steps process, initially characterized 
by the accumulation of liver fat followed by the development of necroinflammation and 
fibrosis (Day CP et al,1998).  
Insulin resistance results in both increased adipose tissue lipolysis and increased hepatic 
lipogenesis leading to lipid accumulation in the hepatocytes, mainly in the form of 
triglycerides and FFAs (Emmanuel A et al, 2009). 
The increased liver deposition of TG and FFAs contributes to lipotoxicity and predisposes 
hepatocytes to the second step: the mythocondrial disfunction and the oxidative stress 
(Emmanuel A et al, 2009). 
A recent study  has emphasized that NAFLD is highly prevalent among psoriasis patients 
and it seems that patients with NAFLD and psoriasis are at higher risk for severe liver 
fibrosis than their age, sex and BMI-matched counterparts with NAFLD without psoriasis 
(Marra M et al, 2007). 
Psoriasis, metabolic syndrome and NAFLD might share a common underlying mechanism 
characterized by a low level inflammatory status characterized by a pro-inflammatory 
cytokines generalized activation (Marra M et al, 2007). 
As in  obesity and insulin resistance, TNF-alpha seems to have a pivotal role: both serum 
and hepatic levels of TNF-alpha are elevated in patients with NAFLD and it is directly 
correlated considering the markers of liver damage (Marra M et al, 2007). 
AST, ALT and mostly AST/ALT ratio are considered important parameters of liver damage 
and they appear correlated to the severity of the hepatic damage to histological disease 
severity.[ Pulzi FBU et al, 2011] 
It has already demonstrated that psoriatic patients with NAFLD show a higher mean 
AST/ALT ratio, a parameter proved to be an independent predictor factor of liver fibrosis in 
NAFLD patients (Angulo P et al, 2007). 
AST serum levels increase more than those of ALT with the progression of the hepatic 
disease; therefore, an higher than 1 AST/ALT ratio may be one element of more advanced 
disease (Vanni E et al, 2010).   
www.intechopen.com
 Metabolic Features in Psoriasis 115 
6. Atherogenic dyslipidemia 
Many evidences suggest a strong link between PsO and abnormalities in fatty acid 
metabolism: psoriatic patients show dyslipidemia with increased plasma cholesterol, 
triglycerides (TG), low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein 
(VLDL) cholesterol, and decreased HDL cholesterol and antioxidant capacity. In particular, 
a recent study has underlined that the dyslipidemic profile could precede the psoriasis 
manifestations (Gottlieb A et al, 2008). 
Studies on lipid profile in psoriatic patients have been conducted since 1994 focusing on the 
presence of a significant content in total cholesterol and of the cholesterol/protein ratio in 
low-density lipoproteins (LDL) and in high-density lipoproteins (HDL) of psoriatic children. 
The compositional changes were associated with alterations of fluidity in LDL and HDL of 
psoriatic patients (Offidani AM et al, 1994). 
In PsO patients, the detection of raised levels of LDL and low levels of HDL cholesterol is 
associated with coronary artery disease and with accelerated mortality for cardiovascular 
disease (Jones SM et al, 2000). 
7. Hypertension 
In  PsO patients a higher occurrence of hypertension compared with controls has been 
reported. The underlying mechanism of hypertension in psoriasis has been discussed and 
multiple hypothesis have been emerged on this topic (Gottlieb A et al, 2008). 
The pathogenesis of hypertension in psoriasis seems to be linked to increased production of 
angiotensinogen by adipose tissue, subsequently converted to angiotensin II through  
angiotensin converting enzyme (ACE) (Armstrong AW et al, 2011). 
ACE  serum levels are increased in psoriasis patients (Gottlieb A et al, 2008). 
Angiotensin II not only promotes salt retention by kidney but also it regulates vascular tone, 
acting a vasoconstrictor and stimulates T-cell proliferation promoting  inflammation and the 
development of atherosclerosis (Armstrong AW et al, 2011). 
The association between psoriasis and hypertension may also be attributed to the increased 
oxidative stress in psoriasis patients. Greater levels of reactive oxygen species can damage 
endothelium-dependent vasodilation (Armstrong AW et al, 2011). 
Other studies emphasized the role of endothelin-1 in hypertension development among PsO 
patients. Endothelin-1 is a protein produced by several different cell types including 
keratinocytes; it induces  blood vessels vasoconstriction increasing blood pressure. In PsO 
patients endothelin-1 expression appears to be altered in lesional skin and serum and 
correlated to psoriasis disease severity (Armstrong AW et al, 2011). 
8. Protrombotic state  
A proinflammatory and/or prothrombotic state has been associated with MetS and PsO, 
probably linked to elevated serum levels of PAI-1, fibrinogen and CRP. Elevated CRP levels 
are induced by IL-6 and they have been shown to be predictive of future CVD in initially 
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healthy individuals, and the risk of CVD in patients with either diabetes or MetS is 
significantly increased in the presence of elevated CRP levels (Gottlieb A et al, 2008). 
9. Anti-TNF-alpha in psoriasis and metabolic syndrome 
TNF-alpha is an inflammatory cytokine promoting inflammation via the activation and 
induction of proinflammatory cytokines (IL-1, IL-6, IL-8) and by the upregulation of 
adhesion molecules on endothelial cells leading to increased leukocyte extravasation 
(Channual J et al, 2009). 
Given that TNF-a show a pivotal role in many inflammatory conditions and that it 
represents one of possible link between psoriasis and metabolic syndrome, theoretically the 
TNF-alpha blockade might have a widespread potential in the treatment of both 
pathological entities (Channual J et al, 2009). 
Although it is well known the TNF-alpha inhibitors efficacy on PsO and Psoriatic arthritis 
(PsA), little is known about their effects on the MetS components in PsO patients. 
Currently, three available in the United States are approved for psoriasis and psoriatic 
arthritis (PsA): infliximab, etanercept, and adalimumab (Channual J et al, 2009). 
Infliximab is a chimeric monoclonal antibody binding the human tumor necrosis factor 
alpha (Staidle JP et al, 2011). 
Actually there are no data in literature about infliximab effect on insulin resistance or 
sensitivity in PsO patients. 
About lipid profiles, studies have shown that infliximab does not significantly modify total 
cholesterol, triglycerides and,  interestingly, the patient’s lipid profile reverted to baseline 
values after infliximab discontinuation (Gisondi P et al, 2008;  Antoniou KM et al, 2008). 
Studies investigating the effect of infliximab on body weight have reported significant 
increase in weight gain and in BMI, without  differences among males and females 
(Saraceno R et al, 2009). 
Etanercept is a fusion protein consisting of two molecules of extracellular domain of  human 
p75 TNF-alpha receptor attached to the Fc domain of  human immunoglobulin G1 (IgG1), 
that binds to TNF-alpha with greater affinity than natural receptor. The binding makes TNF-
alpha  biologically inactive, with consequent reduction of inflammation (Weinberg JM, 
2003). 
Although there are conflicting results on the effect of Etanercept in insulin-resistance, 
etanercept have shown an interesting action on reducing serum insulin levels and 
improving insulin sensitivity. Similar to Infliximab, Etanercept does not significantly modify 
lipid profiles; furthermore, PsO patients treated by etanercept gradually and progressively 
gain weight, in particular lean ones (Marra M et al, 2007). 
Adalimumab is human monoclonal antibody against TNF-alpha (Staidle JP et al, 2011). 
Although there are no reports in literature discussing about adalimumab effect on insulin 
resistance or sensitivity in PsO patients, a recent case revealed episodes of hyperglycemia in 
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a PsO-PsA patient; these increased serum glucose levels resolved after adalimumab 
discontinuation (Wu JJ et al, 2008). 
Similar to Infliximab and Etanercept, Adalimumab does not modify lipid profiles and it 
increases BMI and weight gain (Saraceno R et al, 2009). 
10. Conclusion  
Despite further studies on anti-TNF-alpha drug effect on MetS syndrome are required, an 
examination of literature data suggest that the combined effects of improved insulin 
resistance and sensitivity and a significant reduction in systemic inflammation  may 
interrupt inflammatory cascade linking PsO and MetS. 
Taking into consideration the high potentiality of biological therapies to reduce the 
metabolic effect of TNF-alpha, the future goal might be to demonstrate a real in vivo 
preventing effect on development of cardiovascular comorbidities in Pso/PsA patients. For 
these reason other longitudinal long term clinical studies are needed.  
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